Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:47:10.439Z.
Calculation as of: 2026-10-06T20:47:10.439Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e0aae41c25609cbe98cd8c59fbdc20e812e1ea61d6a67e0b8df2c56749153647
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$369.50M
EV/FCF Ratio
N/A
TTM Avg
17.00x
3Y Avg
16.36x
5Y Avg
16.36x
Market Cap
$380.37M
EV/FCF Ratio
N/A
TTM Avg
1559.86x
3Y Avg
1559.86x
5Y Avg
273.86x
Market Cap
$359.53M
EV/FCF Ratio
N/A
TTM Avg
6.23x
3Y Avg
6.23x
5Y Avg
6.23x
Market Cap
$355.43M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $374.50M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.01M | N/A | N/A | N/A | N/A |
| Zura Bio Limited (ZURA)vs › | $376.19M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | N/A | 17.00x | 16.36x | 16.36x |
| Orthofix Medical Inc. (OFIX)vs › | $380.37M | N/A | 1559.86x | 1559.86x | 273.86x |
| REGENXBIO Inc. (RGNX)vs › | $385.15M | N/A | 8.43x | 8.43x | 81.90x |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | N/A | 6.23x | 6.23x | 6.23x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 12.19x | 33.56x | 51.03x | 195.24x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
